PHESGO SC (Roche Products Pty Ltd)

New combination

Early Breast Cancer (EBC)

PHESGO SC (solution for injection) is indicated in combination with chemotherapy for the:

• neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either > 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer
• adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence

Select patients for therapy based on a validated test.

Metastatic Breast Cancer (MBC)

PHESGO SC is indicated in combination with docetaxel for patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Select patients for therapy based on a validated test.